Medically reviewed by Drugs.com. Last updated on Sep 16, 2020.
(TA floo prost)
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Solution, Ophthalmic [preservative free]:
Zioptan: 0.0015% (10 ea, 30 ea) [contains disodium edta, polysorbate 80]
Brand Names: U.S.
- Ophthalmic Agent, Antiglaucoma
- Prostaglandin, Ophthalmic
Tafluprost acid is a fluorinated prostaglandin F2-alpha analog believed to reduce intraocular pressure by increasing outflow of aqueous humor via the uveoscleral pathway; exact mechanism by which it reduces IOP is unknown.
Through the cornea
Ester prodrug (tafluprost) is hydrolyzed to the biologically active acid metabolite (tafluprost acid); tafluprost acid metabolized further via fatty acid beta oxidation and phase II conjugation
Onset of Action
Reduction of intraocular pressure (IOP): 2 to 4 hours; Peak effect: Maximum reduction of IOP: ~12 hours
Time to Peak
Plasma: ~10 minutes
Use: Labeled Indications
Elevated intraocular pressure: Reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
There are no contraindications listed in the manufacturer’s prescribing information.
Elevated intraocular pressure: Ophthalmic: One drop in the affected eye(s) once daily in the evening; do not exceed the once daily dosage because it has been shown that more frequent administration may decrease the IOP-lowering effect
Refer to adult dosing.
For ophthalmic use only. Wash hands before use. Avoid touching the tip of the single-use container to eye or other surfaces. Each single-use container has adequate solution to treat both eyes (if applicable); discard immediately after use. If more than one topical ophthalmic drug is being used, administer the drugs at least 5 minutes apart.
Store unopened foil pouches refrigerated at 2°C to 8°C (36°F to 46°F). During shipping, may be stored at temperatures up to 40°C (104°F) for no more than 2 days; do not use if mail-order prescriptions arrive after 2 days of the dispensing date. Upon opening the foil pouch, store the single-dose containers at 20°C to 25°C (68°F to 77°F) in the foil pouch; discard unused containers after 30 days. Discard opened single-dose containers immediately after use. Protect from moisture.
Nonsteroidal Anti-Inflammatory Agents: May diminish the therapeutic effect of Prostaglandins (Ophthalmic). Nonsteroidal Anti-Inflammatory Agents may also enhance the therapeutic effects of Prostaglandins (Ophthalmic). Monitor therapy
Nonsteroidal Anti-Inflammatory Agents (Ophthalmic): May diminish the therapeutic effect of Prostaglandins (Ophthalmic). Nonsteroidal Anti-Inflammatory Agents (Ophthalmic) may enhance the therapeutic effect of Prostaglandins (Ophthalmic). Monitor therapy
>10%: Ophthalmic: Conjunctival hyperemia (4% to 20%)
1% to 10%:
Central nervous system: Headache (6%)
Genitourinary: Urinary tract infection (2%)
Infection: Common cold (4%)
Ophthalmic: Eye irritation (≤7%), stinging of eyes (≤7%), conjunctivitis (5%), cataract (3%), eye pain (3%), xerophthalmia (3%), blurred vision (2%), hyperpigmentation of eyelashes (2%), increased eyelash length (2%)
Respiratory: Cough (3%)
<1%, postmarketing, and/or case reports: Dyspnea, exacerbation of asthma, iris hyperpigmentation, iritis, uveitis
Concerns related to adverse effects:
• Ocular effects: May change/increase brown pigmentation of the iris, eyelid, and eyelashes; length, color, thickness, shape, and/or number of eyelashes may also be increased. Pigmentation of the iris is likely to be permanent although iris color change may not be noticeable for months to years; pigmentation of the eyelid and eyelash changes may be reversible following discontinuation of therapy. Long-term consequences and potential injury to eye are not known.
• Ocular disease: Use with caution in patients with intraocular inflammation, aphakic patients, pseudophakic patients with a torn posterior lens capsule, or patients with risk factors for macular edema.
• Pediatric: Use in pediatric patients is not recommended due to possible safety issues of increased pigmentation following long-term use.
Intraocular pressure; regularly examine patients who develop increased iris pigmentation
Ophthalmic prostaglandins, such as tafluprost, have a theoretical risk of miscarriage. To decrease this risk, agents other than tafluprost may be preferred for the treatment of glaucoma in patients planning to become pregnant (Strelow 2020). The manufacturer recommends patients of childbearing potential use effective contraception during treatment with tafluprost
Pregnancy Risk Factor
Ophthalmic prostaglandins, such as tafluprost, are generally avoided during pregnancy due to a theoretical risk of miscarriage and premature labor. Agents other than tafluprost may be preferred for the treatment of glaucoma during pregnancy, especially during the first trimester. In general, if ophthalmic agents are needed in pregnancy, the minimum effective dose should be used in combination with punctal occlusion to decrease exposure to the fetus (Belkin 2020; Prum 2016; Strelow 2020).
What is this drug used for?
• It is used to treat glaucoma.
• It is used to lower high eye pressure.
All drugs may cause side effects. However, many people have no side effects or only have minor side effects. Call your doctor or get medical help if any of these side effects or any other side effects bother you or do not go away:
• Blurred vision
• Eye redness
• Eyelash changes
• Common cold symptoms
• Dry eyes
WARNING/CAUTION: Even though it may be rare, some people may have very bad and sometimes deadly side effects when taking a drug. Tell your doctor or get medical help right away if you have any of the following signs or symptoms that may be related to a very bad side effect:
• Urinary tract infection like blood in the urine, burning or painful urination, passing a lot of urine, fever, lower abdominal pain, or pelvic pain
• Shortness of breath
• Vision changes
• Severe eye irritation
• Eye pain
• Eye discharge
• Eyelid changes
• Eye discoloration
• Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing, swallowing, or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.
Note: This is not a comprehensive list of all side effects. Talk to your doctor if you have questions.
Consumer Information Use and Disclaimer: This information should not be used to decide whether or not to take this medicine or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a limited summary of general information about the medicine's uses from the patient education leaflet and is not intended to be comprehensive. This limited summary does NOT include all information available about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this medicine. This information is not intended to provide medical advice, diagnosis or treatment and does not replace information you receive from the healthcare provider. For a more detailed summary of information about the risks and benefits of using this medicine, please speak with your healthcare provider and review the entire patient education leaflet.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about tafluprost ophthalmic
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Interactions
- En Español
- 10 Reviews
- Drug class: ophthalmic glaucoma agents
Other brands: Zioptan